Testing a new oral drug for radiation proctitis
Part of Digestive system clinical trials.
This trial tests an oral drug called Teslanbaicin for people who have pelvic cancer and developed radiation proctitis (inflammation of the rectum from radiation therapy). The goal is to see if it is safe and helps heal the inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pelvic cancer and received radiation therapy that caused mild to moderate inflammation in your rectum.
- You are 18 years or older and willing to follow the study plan.
- Your blood counts and kidney/liver function are within acceptable ranges as checked by your doctor.
- Your expected survival is at least 6 months, and you are generally active (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug tislelizumab with standard chemotherapy and radiation before surgery to see if it can help patients with low rectal cancer avoid surgery or keep their organs. It is for people whose tumors are close to the anus and have not spread.
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
This trial tests a new combination of radiation and drugs for people with a type of rectal cancer that has not spread. The goal is to shrink the tumor before surgery, using a shorter course of radiation followed by several medicines.
This trial tests whether a special kind of stem cell (called TH-SC01) can help people with long-term rectal damage from pelvic radiation. You will be injected with a small amount of radioactive material attached to the cells so doctors can see where they go and how long they stay in your body.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
Hear when a new Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.